Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy.

Autor: Iwata, Hiroji, Yamamoto, Yutaka, Sakai, Takehiko, Hasegawa, Yoshie, Nakamura, Rikiya, Akabane, Hiromitsu, Ohtani, Shoichiro, Kashiwaba, Masahiro, Taira, Naruto, Toyama, Tatsuya, Fujisawa, Tomomi, Masuda, Norikazu, Shibahara, Yukiko, Sasano, Hironobu, Yamaguchi, Takuhiro
Zdroj: Breast Cancer Research & Treatment; Jun2023, Vol. 199 Issue 2, p231-241, 11p
Abstrakt: Purpose: Neoadjuvant endocrine therapy (NET) is a treatment option for estrogen receptor-positive (ER+) postmenopausal early breast cancer (EBC). This phase III trial evaluated the prognosis of EBC patients treated with/without chemotherapy (CT) following NET. Methods: ER+/HER2−, T1c-2, and clinically node-negative EBC patients were enrolled in 2008–2013 and treated with endocrine therapy (ET) in weeks 24–28. All patients, excluding those with progressive disease (PD) during NET or ≥ 4 positive lymph nodes after surgery, were randomized to ET for 4.5–5 years with/without CT. The primary endpoint was disease-free survival (DFS). Secondary endpoints included distant DFS (DDFS), overall survival (OS), and DFS/DDFS/OS according to clinical response to NET. Results: Of 904 patients, 669 were randomized to CT+ET (n = 333) or ET alone (n = 336). The median follow-up was 7.8 years. DFS (CT+ET, 47 events; ET alone, 70 events) and DDFS did not reach the planned numbers of events. Eight-year DFS/DDFS rates were 86%/93% and 83%/92%, respectively. DFS was significantly better in CT+ET than ET alone in subgroups aged < 60 years (P = 0.016), T2 (P = 0.013), or Ki67 > 20% (P = 0.026). Progesterone receptor and histological grade were predictive markers for clinical responses to NET. Conclusion: NET may be used as standard treatment for patients with ER+EBC. Although it is difficult to decide whether to administer adjuvant CT based solely on the effect of NET, the response to NET may help to inform this decision. Trial registration: This study was registered at the UMIN Clinical Trials Registry under UMIN000001090 (registered 20 March 2008). [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: